Status:
RECRUITING
China Lymphoma Patient Registry Study
Lead Sponsor:
Jun Zhu
Collaborating Sponsors:
Peking University First Hospital
Tianjin Medical University Cancer Hospital
Conditions:
Lymphoma
Eligibility:
All Genders
18+ years
Brief Summary
Lymphoma is the most common hematologic tumor. It is derived from lymphoid tissue, including Hodgkin's lymphoma(HL) and non Hodgkin's lymphoma(NHL). The treatment of lymphoma includes chemotherapy, ra...
Detailed Description
Lymphoma is the most common hematologic tumor. It is derived from lymphoid tissue, including Hodgkin's lymphoma(HL) and non Hodgkin's lymphoma(NHL). The treatment of lymphoma includes chemotherapy, ra...
Eligibility Criteria
Inclusion
- The disease was diagnosed by Hodgkin's or non Hodgkin's lymphoma
- 18 years of age or older at diagnosis
- The diagnosis was confirmed within 6 months before admission
- Informed consent was obtained
Exclusion
- There are no special exclusion criteria in this study
Key Trial Info
Start Date :
May 17 2017
Trial Type :
OBSERVATIONAL
Allocation :
ESTIMATED
End Date :
August 30 2027
Estimated Enrollment :
5000 Patients enrolled
Trial Details
Trial ID
NCT03313271
Start Date
May 17 2017
End Date
August 30 2027
Last Update
October 18 2017
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Peking University Cancer Hospital
Beijing, Beijing Municipality, China, 100142